How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
Number of studies
3
Safety
Requires caution
Time to effects
Not applicable — this is a monitoring schedule, not a therapeutic intervention; the first meaningful follow-up result usually appears around 3 months into therapy.
Who it's for
Table of contents
TL;DR
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
- →Helps catch a dose that's too low or too high before side effects or a lack of therapeutic effect become entrenched
- →Catches rising erythrocytosis at a stage when a dose correction is enough, rather than waiting for clotting complications
- →Enables early detection of concerning PSA dynamics within the window when prostate tissue is most likely to respond to therapy
| 2–4 weeks (optional) | Assessing tolerance and early side effects; lab results usually aren't yet meaningful |
|---|---|
| 3 months | First testosterone measurement (at the right point in the dosing cycle) + hematocrit/CBC; symptom review |
| 6 months | Hematocrit check, symptom review, possible dose adjustment based on results |
| 3–12 months | Prostate cancer risk assessment: PSA + digital rectal exam, with alarm thresholds requiring a urology consult |
| 12 months | Full panel: testosterone, hematocrit, PSA, lipid panel, liver enzymes, symptom review; wraps up the first year of therapy |
| 1–2 years (at-risk group) | Follow-up DEXA scan in patients with osteopenia/osteoporosis or other fracture risk factors |
| Annually once stable | Testosterone, hematocrit, PSA (per standard age-based screening), lipid panel, symptom and tolerance review |
| Any dose or delivery form change | Repeats the check cycle — testosterone and hematocrit measured again about 3 months after the change |
Understand
Overview
Our entry on which tests to run before starting TRT answers a different question — whether therapy is even warranted and safe to begin (we cover the full pre-treatment checklist separately, in the article on testing before TRT). This entry covers an entirely different stage — what happens after the first dose is given. TRT isn't a one-time intervention; it's a lifelong or multi-year therapy, which means monitoring never really ends — only its frequency and scope change depending on the phase of treatment.
The monitoring schedule has three distinct phases. The first, most intensive phase covers the first three months of therapy — the time needed for the dose to reach steady state and to assess whether the chosen dose and delivery form actually put testosterone concentration in the middle of the reference range rather than at its edge. The second phase, spanning months 3 through 12, focuses on long-term safety — hematocrit, the prostate gland, and the metabolic profile, since it's in that first year that these parameters change the most. The third phase, once therapy has stabilized, becomes a lifelong rhythm of annual checkups, supplemented by periodic bone density assessment in long-term patients.
It's important to understand that this schedule isn't a rigid template identical for every patient. The Endocrine Society, the American Urological Association, and other scientific bodies frame it as a general skeleton that the treating physician adapts individually — checking patients with risk factors more often (elevated baseline PSA, borderline hematocrit, obesity, cardiovascular disease) and stable, long-term well-tolerating patients less often. The testosterone delivery form also directly affects exactly when blood should be drawn — measuring hormone levels works differently for intramuscular injections than for gels or patches, given their very different daily or weekly concentration profile.
It's also worth stressing that monitoring during TRT isn't only about numbers on a lab report. Every follow-up visit should include a conversation about symptoms — whether libido, energy, mood, and sexual function have genuinely improved, whether new complaints have appeared (acne, fluid retention, sleep apnea, excessive erythrocytosis showing up as headaches), and whether the patient is still following the prescribed dosing schedule. A testosterone result within normal range without clinical improvement, or alongside worsening side effects, is a signal to modify therapy, not a reason to keep going unchanged.
The goal of this entry is to lay out a practical, complete schedule — what to test, when, and why — from the first weeks of therapy through years of monitoring, distinguishing the specifics of injectable versus transdermal forms. These are general clinical guidelines; the treating physician sets the actual schedule case by case, factoring in the patient's individual risk profile.
Mechanism of action
The logic behind every point in the monitoring schedule comes from testosterone's pharmacokinetics and from how fast various organs and parameters respond to androgen exposure. The first pillar is time to steady state. With intramuscular testosterone injections (enanthate, cypionate), serum concentration doesn't stabilize right away — it usually takes several dosing cycles before a repeatable pattern of peak and trough concentrations settles in. That's why the first measurement assessing dose efficacy is taken no earlier than about three months after starting therapy or after the last dose change — an earlier measurement can give an unrepresentative result and prompt an unnecessary dose correction.
The second pillar is the timing and location of the measurement within the dosing cycle, which differs fundamentally between delivery forms. Injectable testosterone given every 1–2 weeks produces a so-called sawtooth pattern that differs fundamentally from the transdermal profile — concentration rises sharply within 24–72 hours after injection (peak usually around day 2), then gradually falls until the next dose. Measuring right after an injection inflates the result, and measuring right before the next dose (trough) deflates it — so the recommended measurement point is the midpoint between doses (e.g. day 3–4 for weekly injections, day 7 for injections every two weeks), where concentration best reflects average exposure. Transdermal gels and patches give a much more stable, near-physiological daily profile, so measurement can be done on practically any day of therapy, ideally in the morning — but always before that day's dose is applied, not after, to avoid a momentary, artificially inflated reading from the skin at the application site.
The third pillar concerns hematopoiesis. Testosterone intensifies erythropoiesis by stimulating erythropoietin and suppressing hepatic hepcidin, which eases iron absorption. This effect builds up gradually and is most pronounced during the first year of therapy, which is why hematocrit is checked more often early on (at 3 and 6 months), then once a year in stable patients — unless a result approaches the upper limit of normal, which forces more frequent checks, a dose reduction, or a temporary break in therapy. The risk of excessive erythrocytosis is higher with injectable forms (due to high peak concentrations) than with gels, which partly explains why some physicians intensify hematocrit monitoring specifically in patients on injections.
The fourth pillar is prostate tissue. Testosterone doesn't initiate prostate cancer, but androgen-dependent prostate tissue — including a potential subclinical cancer focus — responds to a change in hormone concentration, particularly in the first year of therapy, when levels shift from low to physiological. That's why PSA is checked in the 3–12 month window from the start of therapy, with clearly defined alarm thresholds (a confirmed PSA rise of more than 1.4 ng/mL from baseline, PSA above 4.0 ng/mL, or an abnormal digital rectal exam) that call for a urology consult. After the first year of stable therapy, PSA monitoring reverts to the standard population screening schedule based on the patient's age and race, not on the fact of being on TRT.
The fifth pillar is bone. Testosterone — partly via aromatization to estradiol — supports bone mineral density, and in men with long-standing, untreated hypogonadism that density is often already reduced at baseline. A bone density scan (DEXA) done at the start of therapy provides a reference point, and repeating it after roughly 1–2 years lets you assess whether therapy is actually improving bone density in at-risk patients (documented osteopenia, osteoporosis, or low-trauma fractures in their history) — in patients without such risk factors, routine, frequent DEXA repeats usually aren't warranted. The sixth pillar is metabolism — a lipid panel and liver enzymes are checked periodically, because testosterone therapy can shift the lipid profile, while the metabolic disturbances that often accompany hypogonadism (insulin resistance, obesity) themselves require long-term monitoring independent of TRT.
Early phase (up to 3 months)
Goal: confirm the dose puts testosterone in the middle of the normal range, measured at the right point in the dosing cycle (midpoint between injections, or in the morning before applying gel).
Consolidation phase (3–12 months)
Goal: safety — hematocrit every 3–6 months, prostate risk assessment (PSA + DRE), a first look at metabolic profile and therapy tolerance.
First-year wrap-up (12 months)
A full checkup panel combining all parameters, a decision on the ongoing monitoring schedule, and possible DEXA scanning for at-risk patients.
Long-term phase (past year one)
Annual checks of testosterone, hematocrit, PSA per standard screening, and lipid panel; periodic DEXA for select patients; any dose change resets the check cycle.
Evidence: strong — based on 3 studies in this database.
Benefits
Common myths
MythIf pre-TRT testing came back fine, checkups during therapy can be infrequent.
FactPre-treatment diagnostics assesses baseline status, not the body's response to therapy itself — hematocrit, PSA, and metabolic profile may only shift once testosterone is actually being administered, which is why regular checks during treatment are a separate, necessary part of care.
MythTestosterone can be tested at any point in the dosing cycle with injections.
FactWith injectable forms, concentration fluctuates in a sawtooth cycle — measuring right after an injection inflates the result, and right before the next dose deflates it. A reliable reading comes from the midpoint between doses.
MythAfter a year of well-tolerated therapy, you can stop all further checkups entirely.
FactMonitoring during TRT lasts as long as therapy itself — once stabilized, the frequency drops to annual checks, but it doesn't disappear, since hematocrit or PSA can still shift even after many years of treatment.
MythElevated hematocrit during TRT always means therapy must be stopped immediately.
FactIn many cases a dose reduction, a change of delivery form (e.g. from injections to gel), or a temporary pause is enough, after which therapy can continue under closer monitoring — full discontinuation is a last resort for very high values or no improvement.
Forms & variants
How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Schedule for injectable forms
Requires a precise testosterone measurement timing (midpoint of the dosing cycle) due to the sawtooth concentration pattern; slightly more frequent hematocrit checks in the first year due to higher peak concentrations.
Best for: Patients on intramuscular or subcutaneous testosterone injections every 1–2 weeks
Schedule for transdermal forms (gel, patch)
A more flexible measurement timing (any day of therapy, morning, before application), a more stable concentration profile, usually lower risk of excessive erythrocytosis.
Best for: Patients using testosterone gels or patches who prefer a simpler check schedule
Intensive schedule (elevated risk)
More frequent hematocrit and PSA checks, additional specialist consults (urologist, hematologist, cardiologist) for borderline results.
Best for: Patients with borderline baseline hematocrit or PSA, obesity, cardiovascular disease, or a family history of prostate cancer
Practice
Frequently asked questions
The first follow-up measurement is taken about 3 months after starting therapy or after the last dose change. Once therapy has stabilized, testosterone checks usually happen once a year, unless symptoms suggest the dose is too low or too high.
Pre-TRT testing (covered in a separate entry on testing before testosterone therapy) confirms deficiency and assesses whether it's safe to start. This schedule covers the period already in treatment — checking whether the dose is right and whether therapy stays safe over time.
At the midpoint between doses — for example day 3–4 with weekly injections, or day 7 with injections every two weeks. Measuring right after an injection gives an inflated result, and right before the next dose, a deflated one.
Standardly at months 3 and 6 of therapy, then at least once a year. If a result nears the upper limit of the lab's normal range, the physician usually recommends more frequent checks, regardless of the previously set schedule.
The most intensive PSA monitoring falls in the 3–12 month window from the start of therapy. After that, if the result is stable, monitoring reverts to standard population-level prostate cancer screening, based on the patient's age rather than the fact of being on TRT.
No — it has particular value in men with documented osteopenia, osteoporosis, or a history of low-trauma fractures, in whom it's done at the start of therapy and repeated after 1–2 years. Patients without those risk factors usually don't need routine, frequent DEXA repeats.
Changing the dose or delivery form resets the schedule for monitoring effectiveness — the next meaningful testosterone measurement is again taken about 3 months after the change, not from the original start of therapy.
Not while therapy continues. Once stabilized, testing frequency drops to annual checks, but stopping monitoring entirely isn't recommended — hematocrit, PSA, or metabolic profile can still shift even after many years of treatment.
Dosage & timing
Typical dose
Not applicable — this entry describes the checkup schedule during therapy, not drug dosing
Form
Follow-up blood tests: total testosterone (at the right point in the dosing cycle), hematocrit/CBC, PSA with a digital rectal exam, lipid panel, liver enzymes; periodic DEXA scans for at-risk patients
The first meaningful testosterone measurement is taken no earlier than about 3 months after starting therapy or after a dose change — an earlier result may not reflect steady state. Any change in dose or delivery form resets this three-month counter.
Best times to take it
- Injectable testosterone (enanthate, cypionate): measure at the midpoint between doses (e.g. day 3–4 for weekly injections, day 7 for injections every two weeks), not right after or right before the next injection
- Gel or patch testosterone: measure in the morning, before that day's dose is applied, for a stable reading close to the physiological rhythm
- First assessment of dose efficacy: no earlier than 3 months after starting therapy or after the last dose change
- Hematocrit: checked at months 3 and 6, then at least once a year; more often if the result is nearing the upper limit of normal
- PSA and digital rectal exam: in the 3–12 month window from the start of therapy, then per standard age-based prostate cancer screening
- Bone density scan (DEXA): at the start of therapy for patients with osteoporosis risk factors, repeated after 1–2 years of therapy
What actually helps
Standard schedule per Endocrine Society guidelines
Strong evidenceChecks at months 3 and 6, prostate risk assessment in the 3–12 month window, a full panel after year one, then annual checks.
Simplified schedule for long-term stable patients
Early-stage evidenceIn patients treated for years with no prior abnormalities, some clinicians stretch the interval between full panels to 12–18 months — an individual decision, not a guideline standard.
Periodic bone density scanning for at-risk patients
Moderate evidenceDEXA at the start of therapy and repeated after 1–2 years in men with documented osteopenia, osteoporosis, or a history of low-trauma fractures.
Safety
Side effects & contraindications
Possible side effects
Not applicable — this entry describes a monitoring schedule, not the drug therapy itself
Possible mild discomfort from more frequent blood draws in the first year of therapy
Contraindications
Not applicable pharmacologically — this is a checkup schedule, not an intervention
Skipping hematocrit monitoring in the first year of therapy is considered improper clinical practice, especially with injectable forms
Skipping PSA assessment in the 3–12 month window in men of an age where prostate cancer screening is warranted goes against the guidelines
Interactions
High-dose biotin (vitamin B7) can distort immunoassay-based testosterone and PSA measurements — it's worth stopping the supplement 2–3 days before a follow-up blood draw
Recent ejaculation, cycling, or a digital rectal exam done right before the draw can transiently raise PSA and skew the result
Dehydration and recent intense fluid loss (e.g. sauna, endurance training) can temporarily inflate hematocrit independent of therapy's real effect
Drugs that affect SHBG (e.g. certain anticonvulsants, thyroid hormones) can alter the interpretation of total testosterone without a real change in the biologically active fraction — in such cases it's worth considering a parallel free testosterone measurement
Is it worth taking?
Who it's for
- Men already on TRT who want to understand which tests to expect from their physician, and when
- Patients considering starting therapy who want to know the real, long-term scope of the monitoring commitment involved
- People changing their testosterone dose or delivery form and looking for guidance on when to recheck results
Not for
- Not applicable pharmacologically — this is a checkup schedule, not an intervention
- Skipping hematocrit monitoring in the first year of therapy is considered improper clinical practice, especially with injectable forms
- Skipping PSA assessment in the 3–12 month window in men of an age where prostate cancer screening is warranted goes against the guidelines
Evidence
Worth knowing
The first meaningful testosterone measurement after starting therapy is taken no earlier than 3 months in — an earlier result may not reflect steady state.
With intramuscular injections, the most reliable measurement is taken at the midpoint between doses, not right after or right before the next injection.
The risk of excessive erythrocytosis is highest in the first year of therapy, which is why hematocrit is checked more often then than in later years.
The prostate risk assessment window falls at 3–12 months from the start of therapy — a confirmed PSA rise of more than 1.4 ng/mL from baseline calls for a urology consult.
Any change in dose or delivery form resets the schedule — the next meaningful testosterone measurement again happens about 3 months later.
A bone density scan (DEXA) isn't a routine test for every TRT patient — it makes the most sense in men with documented osteoporosis risk factors.
Studies
Clinicians should evaluate men on testosterone therapy at 3 and 6 months after starting, then at least annually, monitoring symptoms, adverse effects, adherence, and testosterone and hematocrit concentrations.
Bhasin S et al. (Endocrine Society guideline), Journal of Clinical Endocrinology & Metabolism, 2018
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Strong evidenceBhasin S, Brito JP, Cunningham GR et al. · Journal of Clinical Endocrinology & Metabolism · 2018
Clinical guidelines defining a detailed TRT monitoring schedule — checks at months 3 and 6, prostate risk assessment in the 3–12 month window, and annual checks once therapy has stabilized.
View studyEvaluation and Management of Testosterone Deficiency: AUA Guideline
Strong evidenceMulhall JP, Trost LW, Brannigan RE et al. · The Journal of Urology · 2018
American Urological Association guidelines describing the principles of monitoring men during testosterone therapy, including decision thresholds for PSA and hematocrit.
View studyManagement of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide
Moderate evidenceAgrawal P, Singh SM, Kohn T · European Urology Focus · 2023
A practical guide covering the frequency of hematocrit checks during testosterone therapy and the decision thresholds for dose reduction, changing delivery form, or temporarily stopping treatment.
View studySources & bibliography
- Bhasin et al. 2018 — Endocrine Society Guideline
- Mulhall et al. 2018 — AUA Guideline
- Agrawal et al. 2023 — Management of Erythrocytosis
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.6TRT and Hematocrit — Why Does Testosterone Raise It?
A rise in hematocrit is the best-documented side effect of testosterone therapy — it affects as many as one in four men on injections. We walk through the mechanism step by step, explain why the delivery method matters, and look at how this risk is actually managed in clinical practice.
4.7Hematocrit During TRT — What's a Safe Value, and What to Do If It's Elevated?
50%, 52%, 54%, 56% — each of those numbers on a TRT blood panel means something different. A concrete guide to hematocrit thresholds per the Endocrine Society and AUA guidelines: when more frequent monitoring is enough, when to reduce the dose, when to consider phlebotomy, and when to pause therapy.
4.6Testosterone — What's Normal for a Man? Results, Age, and When It Becomes a Problem
The 'normal' range printed on your lab report doesn't mean quite what it seems — reference ranges vary between labs, assay methods, and the population they were derived from. We explain how to actually read a testosterone result, how it changes with age, and when a 'low-normal' result is already a clinical problem.
4.6Total vs. Free Testosterone — Which Result Actually Matters?
Two men with identical total testosterone can have completely different amounts of biologically available hormone. We explain when free testosterone genuinely changes the clinical picture, when it's an unnecessary expense — and why the measurement method matters just as much as the number itself.
4.6SHBG and Testosterone — What Does a High or Low SHBG Level Mean?
The same total testosterone result can mean completely different things in two different people — it all depends on whether their SHBG is high, low, or normal. We explain exactly what raises and lowers SHBG and how to read both results together.
Related articles
PoradnikiThe Most Common TRT Mistakes — 15 Things That Can Undermine Your Therapy's Results
A wrap-up of our entire testosterone therapy series: fifteen common, real mistakes — from diagnostics to discontinuation — that can turn a well-designed TRT protocol into a source of disappointment or genuine health risk.
August 15, 2026
PoradnikiTRT Step by Step — What Does Starting Testosterone Therapy Actually Look Like?
From the first suspicion that "something's off" to a stable maintenance dose usually takes several months, not a few days — we walk through the entire, real process step by step, including the stages that most often disappoint at the start.
August 15, 2026
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
PoradnikiLow Testosterone: 12 Symptoms Men Often Don't Connect to Their Hormones
Fatigue, a flatter mood, trouble building fitness despite training — most men blame these on age, stress, or a lack of willpower. We look at which symptoms are actually worth linking to low testosterone, and why none of them, on its own, proves anything.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.